Mid-term report 2013 - The European LeukemiaNet

European LeukemiaNet Midterm Report, 08-RNP-071
5. Publicity and publications: scientific quality and impact
The ELN recommendations have major impact within the scientific community as shown here
by two examples.
1) The ELN management recommendations for CML are considered internationally
influential by experts in the field. The first two editions have been cited by close to
600 articles each. The 2009 edition in the JCO ranks on position 7 of the “top 50
Most-cited JCO articles from 2009”. The update of the CML recommendations was
revised by an international panel and is released in July 2013. Since interest in these
guidelines is high among hematologists and experts, they will be published as “pocket
card” as the preceding editions. Pocket cards show the diagnosis and treatment
synopsis in a comfortable pocket style format and can be ordered from the NMC.
2) The ELN diagnosis and management recommendations for AML, published in 2010
in Blood (Doehner et al.), have been successful with 383 citations overall (and nearly
100 citations per year, respectively).
6. Future planning, recommendations and conclusions
The ELN is likely to have a durable impact on leukemia research in Europe. Infrastructure
and the productive collaboration provided by the ELN have accomplished a valuable
contribution to progress in the field of leukemia. The ELN will continue in the forefront of
leukemia research, sharing activities with EHA through scientific groups, COST-, ESF
Research Networking - and EU 7th framework programmes (e.g. the project “Next
Generation Sequencing platform for targeted Personalized Therapy of Leukemia" headed by
Prof. Martinelli, Bologna (http://www.ngs-ptl.com)), but also public- private partnerships and
other research activities, challenging current knowledge and aiming for a cure of leukemias.
16